Reasoning
No VCEP applies. The generic ACMG/AMP rule requires a case-control prevalence comparison and, for the specified threshold path, an OR or RR >5.0 with a confidence interval excluding 1.0. The literature packet indexed PS4 candidate papers (PMID:11244483, PMID:11694551, PMID:11920861, PMID:15277431, PMID:15852062, PMID:20301607, PMID:20301750, PMID:25133958, and PMID:32179840), but the supplied verified extracts do not provide exact-variant affected-control counts, an OR/RR, or a 95% CI for NM_006005.3:c.1675G>A (p.Ala559Thr). Therefore no valid numeric inequality can be written: OR/RR is unavailable, so OR/RR > 5.0 and CI excluding 1.0 cannot be assessed. The available gnomAD frequency is a population observation, not a disease case-control comparison by itself.
Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
- literature_pass.json criteria_index lists PMID:11244483, PMID:11694551, PMID:11920861, PMID:15277431, PMID:15852062, PMID:20301607, PMID:20301750, PMID:25133958, and PMID:32179840 as PS4 leads; ai_classified_papers is empty.
- The supplied paper extracts for PMID:26467025 and PMID:33057194 state that neither paper contains WFS1 c.1675G>A/p.(A559T) variant-specific clinical or population evidence.
- gnomAD v4.1 reports population AF 0.00485437 overall and 0.00569220 in European non-Finnish individuals, but no affected-case frequency is supplied for this variant.
Still missing
- Exact-variant affected-case and unaffected/control counts or a directly reported OR/RR with its 95% CI.
- Full-text verification for the PS4-indexed papers lacking a supplied paper_extracts entry.
Sources